Biosyent (TSXV:RX) FCF Margin % : 30.41% (As of Dec. 2024)

View and export this data going back to 1979. Start your Free Trial

What is Biosyent FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biosyent's Free Cash Flow for the three months ended in Dec. 2024 was C$2.68 Mil. Biosyent's Revenue for the three months ended in Dec. 2024 was C$8.80 Mil. Therefore, Biosyent's FCF Margin % for the quarter that ended in Dec. 2024 was 30.41%.

As of today, Biosyent's current FCF Yield % is 3.39%.

The historical rank and industry rank for Biosyent's FCF Margin % or its related term are showing as below:

TSXV:RX' s FCF Margin % Range Over the Past 10 Years
Min: 10.81 Med: 16.57 Max: 30.09
Current: 11.4

During the past 13 years, the highest FCF Margin % of Biosyent was 30.09%. The lowest was 10.81%. And the median was 16.57%.

TSXV:RX's FCF Margin % is ranked better than
77.37% of 972 companies
in the Drug Manufacturers industry
Industry Median: 0.955 vs TSXV:RX: 11.40

Biosyent FCF Margin % Historical Data

The historical data trend for Biosyent's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent FCF Margin % Chart

Biosyent Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

30.09

16.01

15.86

15.45

11.40

Biosyent Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															7.53	12.22	-18.19	20.95	30.41

Competitive Comparison of Biosyent's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosyent's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biosyent's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Biosyent FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biosyent's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	3.993	/	35.031
	=	11.40 %

Biosyent's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	2.675	/	8.797
	=	30.41 %

Biosyent FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biosyent's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BIOYF:USA

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Executives

Peter Douglas Lockhard	Director
Blair Driscoll	10% Security Holder
Merrilyn Joy Driscoll	10% Security Holder
Sean Driscoll	10% Security Holder
Fax Capital Corp.	10% Security Holder
Fax Investments Inc.	10% Security Holder
Federated Capital Corp.	10% Security Holder
Seyed Ahmad Ashrafi	Director
Robert Joseph March	Senior Officer
Sharan Raghubir	Senior Officer
Rene Goehrum	10% Security Holder, Director, Senior Officer
Biosyent Inc.	Issuer
Joost Van Der Mark	Senior Officer
Sara Elford	Director
Alfred D'souza	Director

Biosyent Headlines

No Headlines